GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Antares Pharma Inc (NAS:ATRS) » Definitions » Price-to-Owner-Earnings

Antares Pharma (Antares Pharma) Price-to-Owner-Earnings : 18.03 (As of May. 03, 2024)


View and export this data going back to 1996. Start your Free Trial

What is Antares Pharma Price-to-Owner-Earnings?

As of today (2024-05-03), Antares Pharma's share price is $5.59. Antares Pharma's Owner Earnings per Share (TTM) ended in Mar. 2022 was $0.31. It's Price-to-Owner-Earnings for today is 18.03.


The historical rank and industry rank for Antares Pharma's Price-to-Owner-Earnings or its related term are showing as below:

ATRS' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 9   Med: 70   Max: 421.25
Current: 17.92

During the past 13 years, the highest Price-to-Owner-Earnings of Antares Pharma was 421.25. The lowest was 9.00. And the median was 70.00.


ATRS's Price-to-Owner-Earnings is not ranked
in the Medical Devices & Instruments industry.
Industry Median: 33.32 vs ATRS: 17.92

As of today (2024-05-03), Antares Pharma's share price is $5.59. Antares Pharma's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2022 was $0.24. Therefore, Antares Pharma's PE Ratio for today is 23.29.

As of today (2024-05-03), Antares Pharma's share price is $5.59. Antares Pharma's EPS without NRI for the trailing twelve months (TTM) ended in was $0.24. Therefore, Antares Pharma's PE Ratio without NRI for today is 23.29.

During the past 13 years, Antares Pharma's highest PE Ratio without NRI was 489.00. The lowest was 8.68. And the median was 15.43.


Antares Pharma Price-to-Owner-Earnings Historical Data

The historical data trend for Antares Pharma's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Antares Pharma Price-to-Owner-Earnings Chart

Antares Pharma Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
Price-to-Owner-Earnings
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - 83.13 10.20

Antares Pharma Quarterly Data
Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22
Price-to-Owner-Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 141.72 73.90 27.37 10.20 13.14

Competitive Comparison of Antares Pharma's Price-to-Owner-Earnings

For the Medical Instruments & Supplies subindustry, Antares Pharma's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Antares Pharma's Price-to-Owner-Earnings Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Antares Pharma's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Antares Pharma's Price-to-Owner-Earnings falls into.



Antares Pharma Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Antares Pharma's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=5.59/0.31
=18.03

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Antares Pharma  (NAS:ATRS) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


Antares Pharma Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of Antares Pharma's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


Antares Pharma (Antares Pharma) Business Description

Traded in Other Exchanges
N/A
Address
100 Princeton South, Suite 300, Ewing, NJ, USA, 08628
Antares Pharma Inc is a specialty pharmaceutical company. It is focused on the development and commercialization of self-administered parenteral pharmaceutical products and technologies. The company's products include OTREXUP, Elestrin, Gelnique, Makena, and others.
Executives
Karen L. Smith director C/O JAZZ PHARMACEUTICALS PLC, 5TH FL, WATERLOO EXCHANGE, WATERLOO RD, DUBLIN L2 4 L2
Carmen B Volkart director C/O MODULAR MEDICAL, INC., 16772 WEST BERNARDO DRIVE, SAN DIEGO CA 92127
Peter C Richardson officer: See Remarks 28903 NORTH AVENUE PAINE, VALENCIA CA 91355
Fred M Powell officer: Executive Vice President & CFO C/O BEJING MED-PHARM CORPORATION 600 W. GERMANTOWN PIKE, SUITE 400 PLYMOUTH MEETING PA 19462
Thomas J Garrity director
Roche Robert P Jr director 41 MOORES ROAD FRAZER PA 19355
Leonard S Jacob director C/O INKINE PHARMACEUTICAL COMPANY INC 425 PARK AVENUE NEW YORK NY 10022
Peter J Graham officer: See Remarks 315 E. 72ND ST., APT 5E, NEW YORK NY 10021
Peter Greenleaf director ONE MEDIMMUNE WAY, GAITHERSBURG MD 20878
Anton Gueth director
Robert F Apple director, officer: President & CEO C/O INKLINE PHARMACEUTICAL CO INC SENTRY PARK EAST 1720 WALTON ROAD BLUE BELL PA 19422
Marvin Samson director
Jacques Gonella director C/O ANTARES PHARMA INC 707 EAGLEVIEW BLVD SUITE 414 EXTON PA 19341
James Patrick Tursi officer: EVP, Chief Medical Officer 106 ASHLEY COURT, MOORESTOWN NJ 08057
Keith E Muckenhirn officer: VP/Controller & Interim CFO C/O ANTARES PHARMA, INC. 3905 ANNAPOLIS LANE N, SUITE 105 PLYMOUTH MN 55447